82 related articles for article (PubMed ID: 25503115)
21. PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer.
El Fitori J; Su Y; Büchler P; Ludwig R; Giese NA; Büchler MW; Quentmeier H; Hines OJ; Herr I; Friess H
Cancer; 2007 Oct; 110(7):1457-68. PubMed ID: 17676584
[TBL] [Abstract][Full Text] [Related]
22. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow.
Heiss MM; Simon EH; Beyer BC; Gruetzner KU; Tarabichi A; Babic R; Schildberg FW; Allgayer H
J Clin Oncol; 2002 Apr; 20(8):2005-16. PubMed ID: 11956259
[TBL] [Abstract][Full Text] [Related]
23. Nuclear translocation of fibroblast growth factor receptor 3 and its significance in pancreatic cancer.
Zhou L; Yao LT; Liang ZY; Zhou WX; You L; Shao QQ; Huang S; Guo JC; Zhao YP
Int J Clin Exp Pathol; 2015; 8(11):14640-8. PubMed ID: 26823787
[TBL] [Abstract][Full Text] [Related]
24. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
[TBL] [Abstract][Full Text] [Related]
25. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients.
Eppenberger U; Kueng W; Schlaeppi JM; Roesel JL; Benz C; Mueller H; Matter A; Zuber M; Luescher K; Litschgi M; Schmitt M; Foekens JA; Eppenberger-Castori S
J Clin Oncol; 1998 Sep; 16(9):3129-36. PubMed ID: 9738585
[TBL] [Abstract][Full Text] [Related]
26. Expression of CD44 in pancreatic cancer and its significance.
Li XP; Zhang XW; Zheng LZ; Guo WJ
Int J Clin Exp Pathol; 2015; 8(6):6724-31. PubMed ID: 26261555
[TBL] [Abstract][Full Text] [Related]
27. The novel tumor angiogenic factor, adrenomedullin-2, predicts survival in pancreatic adenocarcinoma.
Hollander LL; Guo X; Salem RR; Cha CH
J Surg Res; 2015 Aug; 197(2):219-24. PubMed ID: 25982376
[TBL] [Abstract][Full Text] [Related]
28. Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer.
Chang YT; Chang MC; Wei SC; Tien YW; Hsu C; Liang PC; Tsao PN; Jan IS; Wong JM
Pancreas; 2008 Aug; 37(2):145-50. PubMed ID: 18665074
[TBL] [Abstract][Full Text] [Related]
29. Toll Like Receptor 2, 4, and 9 Signaling Promotes Autoregulative Tumor Cell Growth and VEGF/PDGF Expression in Human Pancreatic Cancer.
Grimmig T; Moench R; Kreckel J; Haack S; Rueckert F; Rehder R; Tripathi S; Ribas C; Chandraker A; Germer CT; Gasser M; Waaga-Gasser AM
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27941651
[TBL] [Abstract][Full Text] [Related]
30. NR4A1, 2, 3--an orphan nuclear hormone receptor family involved in cell apoptosis and carcinogenesis.
Li QX; Ke N; Sundaram R; Wong-Staal F
Histol Histopathol; 2006 May; 21(5):533-40. PubMed ID: 16493583
[TBL] [Abstract][Full Text] [Related]
31. Expression of nerve growth factor receptors and their prognostic value in human pancreatic cancer.
Zhang Y; Dang C; Ma Q; Shimahara Y
Oncol Rep; 2005 Jul; 14(1):161-71. PubMed ID: 15944784
[TBL] [Abstract][Full Text] [Related]
32. Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer.
Rohrberg KS; Skov BG; Lassen U; Christensen IJ; Høyer-Hansen G; Buysschaert I; Pappot H
Cancer Biomark; 2010; 7(3):141-51. PubMed ID: 21263190
[TBL] [Abstract][Full Text] [Related]
33. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family.
Basu A; Castle VP; Bouziane M; Bhalla K; Haldar S
Cancer Res; 2006 Apr; 66(8):4309-18. PubMed ID: 16618756
[TBL] [Abstract][Full Text] [Related]
34. Association of axon guidance factor semaphorin 3A with poor outcome in pancreatic cancer.
Müller MW; Giese NA; Swiercz JM; Ceyhan GO; Esposito I; Hinz U; Büchler P; Giese T; Büchler MW; Offermanns S; Friess H
Int J Cancer; 2007 Dec; 121(11):2421-33. PubMed ID: 17631638
[TBL] [Abstract][Full Text] [Related]
35. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system.
Chaudhry A; Papanicolaou V; Oberg K; Heldin CH; Funa K
Cancer Res; 1992 Feb; 52(4):1006-12. PubMed ID: 1310635
[TBL] [Abstract][Full Text] [Related]
36. Insulin-like growth factor binding protein (IGFBP) signalling.
Ricort JM
Growth Horm IGF Res; 2004 Aug; 14(4):277-86. PubMed ID: 15231296
[No Abstract] [Full Text] [Related]
37. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
Carriero MV; Franco P; Del Vecchio S; Massa O; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M
Cancer Res; 1994 Oct; 54(20):5445-54. PubMed ID: 7923178
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
[TBL] [Abstract][Full Text] [Related]
39. Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer.
Shrimali D; Shanmugam MK; Kumar AP; Zhang J; Tan BK; Ahn KS; Sethi G
Cancer Lett; 2013 Dec; 341(2):139-49. PubMed ID: 23962559
[TBL] [Abstract][Full Text] [Related]
40. Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro.
Gallicchio MA; Kaun C; Wojta J; Binder B; Bach LA
J Cell Physiol; 2003 Oct; 197(1):131-8. PubMed ID: 12942549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
